Picture of Towngas Smart Energy logo

1083 — Towngas Smart Energy News Story

0.000.00%
hk flag iconLast trade - 00:00
UtilitiesConservativeMid CapNeutral

2022 will be eventful for 'trailblazer' Argenx, KBC says

** KBC maintained its buy rating for Argenx  ARGX.BR  after
the Dutch biopharmaceutical company complemented its Q3 results
with regulatory and commercial announcements 
    ** 9-month revenues and operating income were up, with FY
cash burn guidance confirmed (nGNE4q8rwf)
    ** The efgar drug is nearing US FDA approval in December,
with additional approvals expected next year in Japan and the EU
(nGNX8yk3nH)
    ** The broker labels co's efgar drug as "one of the biggest
drug launches of the year"
    ** Discussions are in place, through partner Zai Lab, to
explore efgar drug approval in China
    ** Co also announced a partnership with Medison for
regulatory filing and commercialisation in Israel
    ** "2022 strikes us as an eventful year for Argenx," the
broker adds, calling co a growing biotech "trailblazer" in
Europe
    **Out of 13 analysts that cover the stock, ten rate it
"strong buy" or "buy, and ​three rate it "hold"    
    
    

 (Reporting by Olivier Sorgho in Gdansk)
 ((olivier.sorgho@tr.com))

Recent news on Towngas Smart Energy

See all news